在中国创新药NewCo交易逐渐升温之际,总部位于成都的康诺亚(02162.HK),从去年7月份以来,这半年内,已干了四笔交易,其中的两笔,还是今年春节前完成的,这也使得公司在行业中出圈。 NewCo模式的核心在于通过设立海外新公司,将创新药的海外权益授权给该新公司,并引入海外资本和国际化管理团队,从而实现产品出海。但进行NewCo的项目,首付款并不高,且多数还处在早期研发阶段,而康诺亚过早将产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."